GBS earnings

- Entered into exclusive agreement with Intelligent Fingerprinting Ltd. (IFP) for screening technology focused on drugs of abuse towards a prospective acquisition - - Completed collection and analysis in a study with coincidental sampling of oral fluid and blood to evaluate the time-course of glucose in oral fluids - - Company to host conference call & webcast today at 4:30 p.m. ET - NEW YORK, Aug. 31, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (NASDAQ:GBS), a life sciences company developing non-invasive, real-time monitoring and diagnostic testing for patients and their primary health practitioners at point of care, today announced its preliminary financial results for the fourth financi

NEW YORK, Aug. 29, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (NASDAQ:GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that it will release its financial results for the fourth quarter and full year ended June 30, 2022, shortly after the NASDAQ market close on Wednesday, August 31. Management will then host a conference call and webcast at 4:30 p.m. ET. Title:GBS Inc. Fourth Quarter and Full Year 2022 Financial Results Conference Call & WebcastDate:Wednesday, August 31, 2022Time:4:30 p.m. ETConference Call Details:Toll-Free: 877-407-3982International: 201-493-6780Conference ID: 1

The trial is single center, prospective study collecting coincident samples of oral fluids and blood to evaluate the time-course of glucose NEW YORK, July 13, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (NASDAQ:GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced completion of sample collection and analysis of glucose in oral fluid and blood samples from their clinical study at the Diabetes Research Institute of Sutter Health's Mills-Peninsula Medical Center (MPMC) in San Mateo, California. GBS will perform subsequent statistical analyses of the correlation of glucose levels amon

- Initiated prospective study to collect coincident samples of oral fluid and blood following IRB approval - - Finalizing site selection at the University of Newcastle campus for the high-tech manufacturing and production facility - - $10.76 Million in Cash, Cash Equivalents, and Marketable Securities as of March 31, 2022, provides estimated runway into H1 2023 - -To host conference call and webcast today at 4:30 p.m. ET- NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (NASDAQ:GBS), a life sciences company developing non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point-of-care, today announced its financial results fo

NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (NASDAQ:GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that it will release its financial results for the third quarter ended March 31, 2022, shortly after the NASDAQ market close on Tuesday, May 10. Management will then host a conference call and webcast at 4:30 p.m. ET. Title:GBS Inc. Third Quarter 2022 Financial Results Conference Call & Webcast  Date:Tuesday, May 10, 2022  Time:4:30 p.m. ET  Conference Call Details:Toll-Free: 855-327-6837International: 631-891-4304Conference ID: 10018968    The conference call

- Discussions underway between the University of Newcastle and GBS to oversee the high-tech manufacturing facility supported by its $4.7 Million Grant Funding Award from Australian Government - - $11.19 Million in Cash, Cash Equivalents, and Marketable Securities as of December 31, 2021, Provides Estimated Runway into H1 2023 - -To Host Conference Call and Webcast Today at 4:30 p.m. ET- NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (NASDAQ:GBS), a life sciences company developing non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point-of-care, today announced its financial results for the second quarter ended December 3

NEW YORK, Feb. 07, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (NASDAQ:GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that it will release its financial results for the second quarter ended December 31, 2021, shortly after the NASDAQ market close on Thursday, February 10. Management will then host a conference call and webcast at 4:30 p.m. ET. Title:GBS, Inc. Second Quarter 2022 Financial Results Conference Call & WebcastDate:Thursday, February 10, 2022Time:4:30 p.m. ETConference Call Details:Toll-Free: 877-407-3982International: 201-493-6780Conference ID: 13726819 The confere

 – Announced Pre-Submission Package sent to the FDA for its Glucose Biosensor Test –  – Clinical Validation Study Results for SARS CoV2 Ab Test –  – Evaluating site locations for build out of high-tech manufacturing facility supported by $4.7 Million Grant Funding from Australian Government –  – $12.6 Million in Cash, Cash Equivalents, and Marketable Securities as of September 30, 2021, Provides Estimated Runway into H1 2023 –  – To Host Conference Call and Webcast Today at 4:30 p.m. ET – NEW YORK, Nov. 11, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (NASDAQ:GBS), a life sciences company developing non-invasive, real-time diagnostic testing in the hands of patients and their primary health pr

NEW YORK, Nov. 01, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (NASDAQ:GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that it will release its financial results for the first quarter ended September 30, 2021, shortly after the NASDAQ market close on Thursday, November 11. Management will then host a conference call and webcast at 4:30 p.m. ET. Title:GBS, Inc. First Quarter 2022 Financial Results Conference Call & Webcast  Date:Thursday, November 11, 2021  Time:4:30 p.m. ET  Conference Call Details:Toll-Free: 877-407-3982International: 201-493-6780Conference ID: 13724335  The con

- Anticipate Emergency Use Submission for SARS-CoV-2Antibody Biosensor Test in the Second Half of 2021- - $14 Million in Cash, Cash Equivalents, and Marketable Securities as of March 31, 2021, Provides Runway into the Second Half of 2022 - - Established a Point-of-Care Test Commercialization Ecosystem with World-Class Healthcare Institutions - - University of Newcastle, The Wyss Institute for Biologically Inspired Engineering and John Hopkins University - NEW YORK, May 14, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (NASDAQ:GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced its